Mon, Feb 26th 2024
CSEM teams up with Nordic innovator ClexBio to pioneer a bioreactor, a leap in lab-cultivated human veins for regenerative medicine.
Invest Western Switzerland have claimed CSEM, in collaboration with ClexBio, has developed a groundbreaking bioreactor prototype. CSEM has over 600 employees across over five locations in Switzerland.
This innovation creates veins from human stem cells. Designed for integration into the patient’s body, these implants evolve into living tissue, enhancing patient recovery and treatment efficacy.
VivoSet, ClexBio’s platform technology, is crucial in this advancement. It engineers tissue with complex architectures, mimicking the natural structure of veins. This synergy with CSEM’s bioreactor design innovation facilitates the tissue vein grafts. Grafts, ready for implantation, offer a regenerative solution without triggering an immune response, marking a significant milestone in medicine.
ClexBio’s experts in regeneration and hydrogels, combined with CSEM’s advanced automation and micro-physiological systems, have created a biodegradable matrix. This matrix is pivotal in generating human tissue.
The Supervene project focuses on automating the fabrication of regenerative medicine and moving from lab to clinical settings. VivoSet’s role in new cell therapy potentials. Emphasises the importance of a closed biosystem for these implants.
With the bioreactor developed by ClexBio is set to proceed with extensive pre-clinical trials in animals, paving the way for human studies and potential widespread clinical application.
English 
German 
French 
Spanish 
Arabic 
